Stock Market & Financial Investment News

News Breaks September 5, 2012 08:59 EDT LLY Eli Lilly upgraded at Bernstein As previously reported, Bernstein upgraded Eli Lilly to Outperform from Market Perform. The firm upgraded shares based on the increased likelihood that solanezumab will eventually make it to market in Alzheimer's disease, its pipeline opportunities, and potential upside if it were to win the Alimta patent challenge. Correct price target is $52, raised from $46. News For LLY From The Last 14 Days Check below for free stories on LLY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2013 07:24 EDT LLY Global Health Care to host a conference Subscribe for More Information May 16, 2013 08:55 EDT LLY BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information May 14, 2013 09:09 EDT LLY Eli Lilly announces CEO John Lechleiter recovering from surgery Subscribe for More Information 07:24 EDT LLY EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. Sign up for a free trial to see the rest of the stories you've been missing.